The bill H. 3096 aims to establish regulations for gene therapy products in South Carolina by adding Chapter 141 to Title 44 of the South Carolina Code of Laws. It defines key terms related to gene therapy, including "gene therapy product," "genetically modified," and "expose." The bill mandates that any product that could potentially act as a gene therapy or alter genetic material must be labeled as a "Potential Gene Therapy Product," while products confirmed to be gene therapy must be labeled as "Gene Therapy Product." The provisions emphasize the importance of disclosure and require that consumers are made aware of these labels.

Additionally, the bill stipulates that manufacturers, sellers, or distributors of products that could expose individuals to genetically modified material must provide information upon written request from residents. This includes details on how individuals may be exposed to such products. Furthermore, entities must obtain fully informed consent from individuals who could be exposed to these products, ensuring they are aware of all benefits, risks, and potential side effects. The act will take effect upon approval by the Governor.